产品
编 号：F756296
分子式：C28H26N2O4S
分子量：486.58
分子式：C28H26N2O4S
分子量：486.58
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2839471-45-1
产品详情
生物活性：
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC50=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research. LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
LPA5 antagonist 1 (intraperitoneal injection; 17.8 mg/kg; once) treatment shows good brain exposure in vivo.LPA5 antagonist 1 (intraperitoneal injection; 5.6, 10, and 17.8 mg/kg; once) treatment reduces mechanical allodynia in inflammatory pain model.Animal Model:CFA-induced inflammatory pain model in Sprague-Dawley rats
Dosage:5.6, 10, and 17.8 mg/kg
Administration:Intraperitoneal injection; 5.6, 10, and 17.8 mg/kg; once
Result:Reduced mechanical allodynia in a dose-dependent manner.
Animal Model:Male Sprague-Dawley rats
Dosage:17.8 mg/kg
Administration:Intraperitoneal injection; 17.8 mg/kg; once
Result:Showed brain concentrations of 652 ng/mL, after treatment 30 minutes.
体外研究：
LPA5 antagonist 2 (0-10 μM) inhibits hLPA5 calcium mobilization with an IC50 value of 32 nM.LPA5 antagonist 2 (0-10 μM) shows good target selectivity for LPA5.
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC50=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research. LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
LPA5 antagonist 1 (intraperitoneal injection; 17.8 mg/kg; once) treatment shows good brain exposure in vivo.LPA5 antagonist 1 (intraperitoneal injection; 5.6, 10, and 17.8 mg/kg; once) treatment reduces mechanical allodynia in inflammatory pain model.Animal Model:CFA-induced inflammatory pain model in Sprague-Dawley rats
Dosage:5.6, 10, and 17.8 mg/kg
Administration:Intraperitoneal injection; 5.6, 10, and 17.8 mg/kg; once
Result:Reduced mechanical allodynia in a dose-dependent manner.
Animal Model:Male Sprague-Dawley rats
Dosage:17.8 mg/kg
Administration:Intraperitoneal injection; 17.8 mg/kg; once
Result:Showed brain concentrations of 652 ng/mL, after treatment 30 minutes.
体外研究：
LPA5 antagonist 2 (0-10 μM) inhibits hLPA5 calcium mobilization with an IC50 value of 32 nM.LPA5 antagonist 2 (0-10 μM) shows good target selectivity for LPA5.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备